Departamento académico: (FM) Hematología

Centro académico: Facultad de Medicina (FM)

Centro clínico de la Universidad de Navarra: Cancer Center Clínica Universidad de Navarra (CCUN)

Centro / Instituto vinculado a la Universidad de Navarra: Cima Universidad de Navarra

Organización: Universidad de Navarra

Research group: Terapias Basadas en Citoquinas

Email: pberraondol@unav.es

Personal web / Curriculum Vitae: https://cima.cun.es/investigacion/programas-investigacion...

Doctor by the Universidad de Navarra with the thesis Diseño produccion y evaluacion de un virus adenoasociado que expresa interferon alfa para el tratamiento de la hepatitis cronica b 2004. Supervised by Dr. Gloria González Aseguinolaza, Dr. Juan Ruiz Echeverria.

Pedro Berraondo is a scientist specializing in immunotherapy and cytokine-based treatments. He earned his Pharmacy degree from the University of Navarra in 1999 and completed his Ph.D. there in 2004. His doctoral research focused on developing and assessing an adeno-associated virus expressing interferon-alpha for chronic hepatitis treatment in the woodchuck model. Following his Ph.D., Pedro expanded his expertise at the Pasteur Institute in Paris under the mentorship of Dr. Claude Leclerc. There, he pioneered innovative tumor immunotherapy strategies as part of the European THERAVAC project. In February 2007, Pedro joined the Immunology and Immunotherapy Program at Cima Universidad de Navarra, where he leads the Cytokine-based Immunotherapy Laboratory. His contributions to the field are substantial, co-inventing 11 patents and authoring over 180 publications in high-impact journals such as Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. Recognized for his academic and research excellence, Pedro was accredited as a full professor by ANECA in 2024 and received the I3 certification in 2022. He also coordinates the immuno-oncology work module at CIBERONC.